Sernova Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Sernova wird ein Gewinn- und Umsatzwachstum von 61.4% bzw. 60.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 60.4% pro Jahr wachsen soll.

Wichtige Informationen

61.4%

Wachstumsrate der Gewinne

60.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	60.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

OTCPK:SEOV.F - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CAD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
10/31/2027	76	26	N/A	N/A	2
10/31/2026	0	-27	N/A	N/A	3
10/31/2025	10	-16	-1	-1	3
10/31/2024	N/A	-38	-23	-23	4
7/31/2024	N/A	-39	-26	-26	N/A
4/30/2024	N/A	-41	-27	-27	N/A
1/31/2024	N/A	-41	-29	-29	N/A
10/31/2023	N/A	-39	-30	-30	N/A
7/31/2023	N/A	-36	-24	-24	N/A
4/30/2023	N/A	-31	-24	-24	N/A
1/31/2023	N/A	-27	-18	-18	N/A
10/31/2022	N/A	-24	-15	-14	N/A
7/31/2022	N/A	-18	-12	-12	N/A
4/30/2022	N/A	-14	-9	-9	N/A
1/31/2022	N/A	-11	-8	-8	N/A
10/31/2021	N/A	-7	-7	-7	N/A
7/31/2021	N/A	-6	-6	-6	N/A
4/30/2021	N/A	-5	-6	-5	N/A
1/31/2021	N/A	-5	-5	-4	N/A
10/31/2020	N/A	-5	-5	-4	N/A
7/31/2020	N/A	-6	-6	-5	N/A
4/30/2020	N/A	-6	-5	-5	N/A
1/31/2020	N/A	-5	-5	-5	N/A
10/31/2019	N/A	-4	-4	-4	N/A
7/31/2019	N/A	-3	-3	-3	N/A
4/30/2019	N/A	-3	-4	-4	N/A
1/31/2019	N/A	-4	-4	-4	N/A
10/31/2018	N/A	-4	-4	-4	N/A
7/31/2018	N/A	-4	-4	-3	N/A
4/30/2018	N/A	-3	N/A	-3	N/A
1/31/2018	N/A	-3	N/A	-3	N/A
10/31/2017	N/A	-3	N/A	-3	N/A
7/31/2017	N/A	-2	N/A	-3	N/A
4/30/2017	N/A	-2	N/A	-3	N/A
1/31/2017	N/A	-2	N/A	-3	N/A
10/31/2016	N/A	-2	N/A	-3	N/A
7/31/2016	N/A	-3	N/A	-2	N/A
4/30/2016	N/A	-3	N/A	-2	N/A
1/31/2016	N/A	-3	N/A	-2	N/A
10/31/2015	N/A	-3	N/A	-2	N/A
7/31/2015	N/A	-3	N/A	-2	N/A
4/30/2015	N/A	-3	N/A	-2	N/A
1/31/2015	N/A	-3	N/A	-2	N/A
10/31/2014	N/A	-3	N/A	-2	N/A
7/31/2014	N/A	-3	N/A	-1	N/A
4/30/2014	N/A	-2	N/A	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SEOV.F wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.6%).

Ertrag vs. Markt: SEOV.F wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: SEOV.F wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: SEOV.FDie Einnahmen des Unternehmens (60.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: SEOV.FDie Einnahmen des Unternehmens (60.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SEOV.F in 3 Jahren voraussichtlich hoch sein wird

Sernova Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Sernova Corp. Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sernova Corp. announced that it has received CAD 5.2 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

Sernova Corp., Annual General Meeting, Apr 30, 2024

Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting

Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™? at American Diabetes Association 83rd Scientific Sessions

Sernova Corp. Announces Executive Changes

Sernova Corp., Annual General Meeting, Apr 27, 2023

Sernova Announces Advancements with Its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Sernova Corp. Announces Executive Changes

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of Its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

Sernova Corp. Appoints Daniel Mahony, Ph.D. to Its Board of Directors, Effective from September 30, 2022

Sernova Corp. Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System Tm at American Diabetes Association 82nd Scientific Sessions 2022

Sernova Corp.(TSXV:SVA) dropped from S&P/TSX Venture Composite Index

Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evotec SE

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation At American Diabetes Association 82Nd Scientific Sessions 2022

Sernova Corp., Annual General Meeting, Apr 28, 2022

Sernova Corp. Announces Publication of A Peer Reviewed Preclinical Study Demonstrating Positive Results of A Novel Cell Pouch System Cell Therapy

Sernova Corp. Provides Progress Update on Its Phase 1/2 T1d Clinical Trial

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Sernova Corp. has completed a Composite Units Offering in the amount of CAD 20.04 million.

Sernova Corp Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System Clinical Trial and Recommendation for Protocol Continuation

Sernova Corp. Announces Collaboration Agreements with Multiple Pharmaceutical Industry Leaders

Sernova Corp. Provides Clinical Update on U.S. Phase I/II Cell Pouch Trial for Type 1 Diabetes

Sernova Corp. announced that it has received CAD 3.6655 million in funding

Sernova Corp. announced that it expects to receive CAD 3 million in funding

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken